Tamoxifen is an estrogen receptor (ER) agonist used to treat breast cancer; mutations in ER and overexpression of the transcription co-activator MED1 lead to acquired drug resistance and poor prognosis (Nagalingam et al., 2012). This evidence concerns the gene ESR1 and breast carcinoma.